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factors both p53 dependent and independent. In contrast, the MMR-dependent transcriptional response
in 293T Lalpha cells was substantially less pronounced than in TK6 cells, despite an efficient induction of
a G(2)-M checkpoint and nonapoptotic cell death. Thus, we demonstrate that in human cells of different
origin, MMR-mediated killing by methylating agents occurs through different pathways and regardless
of the p53 status. Moreover, once DNA methylation damage has been processed by the MMR system,
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ABSTRACT
DNA mismatch repair (MMR) plays a key role in the cytotoxic response
of human cells to methylating agents, however, the cascade of events
leading to cell cycle arrest and cell death has yet to be characterized. We
studied the role of MMR in the transcriptional response to DNA methy-
lation damage in two human cellular models: (a) the lymphoblastoid cell
line TK6 and its derivative MT1, which is mutated in the MMR gene
hMSH6; and (b) the epithelial cell line 293T L in which the expression of
the MMR gene hMLH1 can be tightly regulated and p53 is inactivated.
Upon N-methyl-N-nitro-N-nitrosoguanidine treatment, only cells with
functional MMR were killed, but the type of cytotoxic response differed.
In TK6 cells, S-phase arrest and apoptosis were accompanied by a dra-
matic change in gene expression, notably, an up-regulation of several
genes encoding growth inhibitors and proapoptotic factors both p53 de-
pendent and independent. In contrast, the MMR-dependent transcrip-
tional response in 293T L cells was substantially less pronounced than in
TK6 cells, despite an efficient induction of a G2-M checkpoint and non-
apoptotic cell death. Thus, we demonstrate that in human cells of different
origin, MMR-mediated killing by methylating agents occurs through dif-
ferent pathways and regardless of the p53 status. Moreover, once DNA
methylation damage has been processed by the MMR system, tumor cells
might be committed to die, although one or more of their signaling
pathways are impaired.
INTRODUCTION
Alkylating agents were introduced into clinical practice  50 years
ago when their antitumor properties, linked to their ability to co-
valently modify nucleophilic centers in DNA, were demonstrated. A
subgroup of these agents, mainly hydrazine and triazine derivatives
MNNG,3 N-methyl-N-nitrosourea, and temozolomide, have one reac-
tive group and react with only one strand of DNA. The reaction
primarily associated with the mutagenicity of these agents is the
methylation of the O6 position of guanines in DNA. When the methyl
group is not removed by the detoxifying enzyme MGMT, O6-meth-
ylguanine can mispair with thymine during DNA replication, which
results in G/C to A/T transitions. Paradoxically, the cytotoxicity of
methylating agents has been attributed to the antimutagenic attempts
of the MMR system to process these O6-meG/T mismatches, the
hypothesis being that mismatch correction directed to the newly
synthesized strand (carrying the thymine) would be ineffectual as long
as the methylated base in the template strand persists. Reiterated
cycles of MMR-driven exonucleolytic degradation of the newly syn-
thesized strand, followed by DNA synthesis and reintroduction of T
opposite to O6-meG, are presumed to result in cell cycle arrest and
lethality (1). Whether this hypothesis is correct, a characteristic phe-
notype of the MMR-deficient human cells, i.e., tolerance to mono-
functional methylating agents, corroborates a relationship between
methylation-induced killing and repair attempts. This phenotype was
first described in 1993 in two seminal works in which N-methyl-N-
nitrosourea-tolerant human and rodent cell lines were found to be
defective in DNA mismatch binding (2), and the MMR-deficient
human lymphoblastoid MT1 cell line showed G/C to A/T transitions
in the HPRT gene upon MNNG treatment (3). Consistent with these
findings, the sensitivity to MNNG in the MMR-deficient human colon
cancer cell line HCT116 (mutated in both alleles of the MMR gene
hMLH1) was restored by expression of a functional hMLH1 gene in a
chromosome transfer experiment (4, 5). A series of studies followed
in which the methylation-tolerance phenotype was confirmed in all
human and rodent cells with impaired MMR, regardless of the MMR
gene mutated (hMSH2, hMSH6, hMLH1, or hPMS2; Ref. 6). The
relationship between MMR deficiency and tolerance to methylating
agents could recently be verified in a truly isogenic cellular model, the
293T L cell line established in our laboratory in which the expres-
sion of hMLH1 can be tightly regulated (7).
The clinical implications of these studies are that tumors with
nonfunctional MMR (15% of colon cancers) should not be respon-
sive to deployment of methylating agents, and MMR-deficient cells in
a tumor might be selected for during such treatment (6). The other
known causes of reduced cellular sensitivity to methylating agents are
typical resistance mechanisms acting upstream of O6-meG/T mispair-
ing, one being the overexpression of MGMT. This enzyme plays an
important role in DNA detoxification by removing methyl- and other
small alkyl groups from the O6 position of guanine. Thus, tumors with
functional MMR and low levels of MGMT should respond favorably
to methylating agents. This situation arises rather frequently because
the levels of MGMT vary widely among individuals. Moreover, the
MGMT gene was shown to be silenced by promoter methylation in
many tumor types, i.e., in 40% of MMR-proficient colorectal can-
cers (8). However, as the sensitivity to methylating agents ultimately
depends on the processing of the damage by MMR, it is crucial to
identify the cascade of events that is triggered by this repair process
and that ultimately leads to cell death. To date, it has been demon-
strated that p53 is stabilized and apoptosis is induced in the MMR-
proficient lymphoblastoid cell line TK6 (9), that MNNG-induced
apoptosis depends on the function of the hMSH2/hMSH6 mismatch
recognition heterodimer and occurs also in TK6 cells in the absence of
p53 (10), and that p53 phosphorylation on serine residues 15 and 392
is dependent on the presence of functional hMSH2/hMSH6 and
hMLH1/hPMS2 complexes (11). To gain more insight into the MMR-
mediated cytotoxicity of methylating agents, we investigated the
global transcriptional response to MNNG in cell lines harboring
diverse combinations of MMR- and p53 status, all devoid of MGMT.
MATERIALS AND METHODS
Cell Lines. The human B lymphoblastoid cell lines TK6 and MT1 were a
gift of William G. Thilly (Massachusetts Institute of Technology, Cambridge,
MA), and WTK1 was kindly provided by Phaik Morgenthaler (University of
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Lausanne, Lausanne, Switzerland). These cells were cultured at 37°C in a 5%
CO2 humidified atmosphere and maintained in RPMI 1640 supplemented with
10% FCS and 2 mM L-glutamine (Life Technologies, Inc.). The cell line 293T
L/L was recently developed in our laboratory (7) from HEK293T human
embryonic kidney cells, immortalized with adenovirus 5 DNA, and addition-
ally transfected with large T antigen from SV40 (12). The hMLH1 gene in this
line is epigenetically silenced by promoter hypermethylation (13). hMLH1
cDNA was stably introduced into this line under the control of the tetracycline
response promoter, using the Tet-Off system (Clontech). In the absence of
doxycycline, this cell line expresses the wild-type hMLH1 protein and is MMR
proficient (293T L), whereas the addition of doxycycline specifically turns
off hMLH1 expression (293T L) and brings about MMR deficiency. These
cells were cultured at 37°C in a 5% CO2-humidified atmosphere and main-
tained in DMEM (Life Technologies, Inc.) supplemented with 10% tetracy-
cline-free FCS (Clontech), 2 mM L-glutamine, 300 g/ml hygromycin B
(Roche), 100 g/ml Zeocin (Invitrogen), and 50 ng/ml doxycycline when
necessary (Clontech).
Cell Cycle Analysis. A total of 1.2  106 cells was washed with PBS and
fixed in ice-cold 70% ethanol. They were treated with 200 units/ml RNase A
and stained with 20 g/ml propidium iodide. Cell cycle analysis was per-
formed using a Becton Dickinson FACscan flow cytometer and Cell Quest
software.
Pulse Field Gel Electrophoresis. Cells were washed and mixed with low
melting agarose at 43°C. Agarose plugs were incubated overnight at 50°C with
gentle agitation in lysis buffer [100 mM EDTA (pH 8), 10 mM Tris-HCl (pH
8.0), 1% sarcosyl, and 100 g/ml proteinase K] followed by a second over-
night incubation at 37°C with fresh lysis buffer. After equilibration in TBE
buffer, the agarose plugs were loaded in the wells of 1% pulse field-certified
agarose (Bio-Rad) in TBE buffer. Electrophoresis was carried out in the
CHEF-DR III Pulse Field Electrophoresis System (Bio-Rad) as follows: 14°C,
switch time 50–90 s, run time 22 h, angle 120°, and voltage gradient 6 V/cm.
Finally, the DNA was stained with ethidium bromide in TBE buffer.
Microscopy. Cells were plated on coverslips in 6-well culture plates and
exposed to MNNG at 37°C in a 5% CO2-humidified atmosphere. After fixation
with 3.7% formaldehyde/PBS for 15 min at 4°C and washing with PBS,
4,6-diamidino-2-phenylindole hydrochloride (Sigma) was added (0.1 g/ml)
for 30 min at 37°C. Finally, the coverslips were mounted in 50% glycerol, and
DNA morphology was examined by fluorescence microscopy (Leica DC 200).
Microarray Experiments. Total RNA was isolated from 5  106 TK6,
MT1, or WTK1 cells, untreated or 30 h after treatment with 0.4 M MNNG or
from 7  106 293T L or L cells, untreated, or 12, 30, and 72 h after 0.2
M MNNG treatment, using an affinity resin column (RNeasy; Qiagen). Total
RNA was converted to cDNA using a cDNA synthesis kit (Invitrogen).
Double-stranded cDNA was then converted to biotin-labeled cRNA by a T7
RNA polymerase-catalyzed reaction (MEGA Script; Ambion) with biotin-
containing ribonucleotides (LOXO). Labeled cRNAs were then purified
(RNeasy; Qiagen) and fragmented. Fifteen g of cRNA were used to hybridize
with Affymetrix U95Av2 chips (Affymetrix) carrying in situ synthesized
oligonucleotides representing 12,000 functionally characterized sequences.
Data Analysis. Expression profiles were analyzed in three independent
experiments using the Data Mining Tool software (Affymetrix). For each
comparison, three ELs, e.g., treated cells, were compared with three BLs, e.g.,
untreated cells. Data were evaluated with both the absolute analysis and the
comparative analysis algorithms. The former algorithm measures, for each
array, the abundance of transcripts (signal) and the specificity of hybridization
(P  present, M  marginally present, A  absent). The latter algorithm
compares two arrays (one EL versus one BL, e.g., nine comparisons for three
arrays/group) and indicates, for each gene, the direction of the change (I  in-
creased, MI  moderately increased, NC  not changed, MD  moderately
decreased, D  decreased).
To eliminate genes with low abundance and specificity of hybridization and
to identify significant changes, we used a two-step selection procedure. For
TK6 and MT1 cells in which only one time point after treatment was evaluated,
in the first step, we compared three ELs versus three BLs and selected genes
matching all of the following four criteria: (a) at least one P or M of the 6
arrays; (b) signal  50 in at least one of these arrays; (c) fold change 1.8 or
-1.8 (average signal of three ELs versus three BLs); and (d) Mann Whitney
P  0.05. In the second step, the selected genes were filtered using an arbitrary
score system based on: (a) signal: average EL for up-regulated genes (or
average BL for down-regulated) 1000, 1000  100, or 100 (points 2, 1, or
0, respectively); (b) number of “P  M”: 3, 2, or 1 (points 2, 1, or 0,
respectively) in the three ELs for up-regulated genes (or in the three BLs for
down-regulated); (c) number of “I  MI” in nine comparisons (for up-
regulation) or “D  MD” (for down-regulation): points 3 (from seven to nine
times), 2 (from four to six), 1 (from one to three), and 0 (all NC). With a
maximum of seven points, a score  4 was considered significant. The same
procedure was applied in the comparison between untreated MT1 and TK6
where MT1 were considered the EL.
For 293T L

cells in which four time points were analyzed (time point 0,
untreated; time points 12, 30, and 72 h after treatment), the two-step selection
procedure was applied to the following comparisons: 293T L versus L at
0, 12, 30, and 72 h, and untreated versus treated (time point 0 versus each time
point after treatment for both L and L). Genes with score  4 were then
analyzed with multiple linear regression to estimate the independent role of
each of the explanatory variables (presence of MLH1 and time after treatment)
on the change of the signal.
Quantitative RT-PCR. One-step RT-real time PCR was performed with
the Roche LightCycler System using the Light Cycle-RNA Master Sybr Green
I Kit (Roche) according to the manufacturer’s instructions, 0.3 M of each
oligonucleotide primer (Microsynth) and 300 ng of total RNA in 20 l of
reaction volume. Primer sequences and RT-PCR reaction conditions are avail-
able on request. The cycle corresponding to the beginning of the log-phase
amplification was denominated TAC. One cycle difference in TAC corre-
sponds theoretically to a 2-fold change in RNA concentration. Fold changes
were obtained by normalizing to GAPDH used as internal reference. All of the
experiments were performed in duplicate, and the specificity of each amplifi-
cation product was verified by agarose gel electrophoresis.
Western Blotting. Western blotting was performed as previously de-
scribed (7) by using the following primary antibodies: TFIIHp89, Santa Cruz
Biotechnology sc-293; -tubulin, Santa Cruz Biotechnology sc-5274; p53,
Santa Cruz Biotechnology sc-98; PIG3, Oncogene Research OP148; p21,
05-345 Upstate; c-myc, Santa Cruz Biotechnology sc-40; bcl-2, Transduction
Laboratories 610538; XPC, kindly provided by Jan Hoeijmakers; PARP,
Calbiochem AM30; hPMS2 PharMingen 556415; and hMLH1 PharMingen
554072.
RESULTS
The lymphoblastoid cell line MT1 was derived from TK6 cells by
treatment with the Acridine ICR191 and selection for resistant clones
with MNNG (14). MT1 cells are MMR deficient because both alleles
of hMSH6 carry different missense mutations (15). We exposed both
cell lines to 0.4 M MNNG (IC90 for TK6) and evaluated the cell
cycle distribution by flow cytometry. TK6 cells accumulated in S
phase as early as 24 h after treatment (Fig. 1A). The sub-G1 peak
observed at later time points, along with the presence of DNA frag-
mentation (Fig. 1D) and PARP cleavage (Fig. 1E), was indicative of
apoptosis induction. In contrast, the cell cycle distribution was com-
pletely unaffected in MT1 cells (Fig. 1A).
RNA was isolated from TK6 and MT1 cells 30 h after treatment
because at this time point the significant changes observed in cell
cycle perturbation were expected to be accompanied by alterations in
the transcriptome. In Fig. 2, the scatter graphs show an overview of
the gene expression changes in TK6 (A) and MT1 (B) upon treatment.
A dramatic change in the transcriptome of TK6 cells contrasted with
the stability of RNA levels in MT1 cells. Applying the two-step
selection procedure described in “Materials and Methods,” we did not
find statistically significant changes in MT1 cells, whereas 340 genes
were up-regulated or down-regulated 1.8-fold in TK6 cells (Table
A, supplementary material). A selection of these genes is listed in
Table 1, categorized according to their putative function. In accord-
ance with the cellular response observed, among up-regulated tran-
scripts were the products of several proapoptotic genes (PIG3,
PUMA, BAX, Fas/APO1, and TNFSF10), cell cycle regulators (p21/
WAF1, GADD45, 14-3-3, SMAD5, SMAD3, and CDC6 and growth
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inhibitors (MIC-1, CEACAM1, BTG2, BTG1, and TIEG). The DNA
repair genes XP-C, DDB2, RAD51 L3, ligase I, and BRCA2 were
also up-regulated, along with several genes involved in metabolism,
cytoskeleton organization, and transcription. As shown in Fig. 2C, we
could verify the reliability of the microarray data by quantitative
RT-PCR for all of the genes tested. Furthermore, most of the genes
found differentially regulated in a previous study using subtractive
hybridization and Northern blot (our unpublished results) were iden-
tified in this study.
In accordance with the increase of p53 protein in TK6 cells (Fig.
2D), we detected up-regulation of the transcripts of many p53-target
genes (Table 1) and for some such as PIG3 and XP-C for which
antibodies were available, an increase in protein levels was also
observed (Fig. 2, D and F, respectively). Conversely, the protein level
of the p53-target p21/WAF1 (Fig. 2D) was unchanged until 72 h after
treatment, despite the early rise in RNA level. To investigate the role
of p53 in the transcriptional response of lymphoblastoid cells to
MNNG, we examined the MMR-proficient WTK1 cells, which were
derived from the same progenitor as TK6 but harbor a homozygous
missense mutation in the p53 gene that leads to overexpression of an
inactive form of the protein (16). Treatment of WTK1 cells arrested
them in S phase and precipitated apoptosis, but the appearance of
apoptotic cells was delayed by 24 h as compared with TK6 (Fig. 1, B
and D), as reported earlier (10). Microarray analysis (Table 1, genes
in bold, and Table C, supplementary material) showed a p53-inde-
pendent up-regulation of several cell cycle regulators and proapo-
ptotic factors in WTK1 cells (see “Discussion”).
In TK6 cells, the most down-regulated gene was c-myc, a promoter
of cell cycle progression (17), the protein level of which dramatically
decreased (Fig. 2E), presumably via repression mediated by the
TGF- effectors SMADs (18). Among the other down-regulated
genes were growth stimulators (IRF4, INSIG1 and INSR) and cell
cycle modulators (DIM1 and cyclin B1), as well as transcripts of four
heat shock proteins, which play a role in preventing apoptosis (19).
Because MT1 was derived from TK6, it was important to know
to what extent the two cell lines could be considered isogenic.
Comparison of their basal gene expression profiles (Fig. 2I)
showed noticeable differences, and after the two-step selection
procedure, we identified several significant changes (Table B,
supplementary material) that might contribute to the absence of
any detectable effect of MNNG on MT1. Among the overexpressed
genes, we found the antiapoptotic factors CD44 (different isoforms
increased between 10- and 44-fold) and Bcl-2 (confirmed at pro-
tein level in Fig. 2G), whereas some proapoptotic molecules
(BNIP3L, CD20, DAPK1, caspase-6, and TNFRSF9) and growth
inhibitors (GADD45 A and B, GAS-7) were underexpressed. In an
attempt to test the integrity of the p53-dependent signaling, we
treated MT1 cells with 23 M MNNG (IC90 for this cell line). This
dose efficiently induced p53 stabilization and transcription of its
targets p21/WAF1, PIG3, and XP-C (Fig. 2, F and H).
These results prompted us to use the isogenic system consisting of
the hMLH1-negative 293T cell line in which the expression of the
stably transfected hMLH1 gene can be induced by doxycycline with-
drawal. In this cell line, p53 is inactivated, and the apoptotic response
is likely to be impaired, as witnessed also by its extreme resistance to
Fas ligand treatment (our unpublished results). To rule out secondary
changes in the transcriptome induced by the overexpression of
hMLH1, we compared the RNA population of 293T L with that of
L cells. The isogenicity of this cellular system was demonstrated
by the very narrow distribution of the transcripts along the central
diagonal line (Fig. 2J) and additionally confirmed by the absence of
significant gene expression differences (i.e., score  4) showed by the
two-step-selection procedure, with the notable exception of hMLH1.
Also, the exposure to doxycycline in the absence of the vector
carrying hMLH1 did not induce any changes in transcript levels (Fig.
1, supplementary material).
The treatment of 293T L cells with 0.2 M MNNG (IC90 for
L) caused a perturbation in the cell cycle (Fig. 1C) and finally
Fig. 1. Flow-cytometric analysis of cell cycle progression of TK6, MT1 (A), WTK1
(B), and 293T L/L (C) cells after treatment with MNNG. TK6 and WTK1 under-
went an S-phase arrest, whereas 293T L cells arrested in G2-M. No alteration in cell
cycle progression was observed in MT1 and 293T L cells. D, DNA fragmentation
analysis by Pulse Field Gel Electrophoresis. Only TK6 and WTK1 cells showed DNA
fragmentation (50 kb) 72 h after MNNG treatment. E, Western blot showing cleavage
of PARP to the characteristic Mr 89,000 fragment in TK6 cells 72 h after treatment. F,
4,6-diamidino-2-phenylindole hydrochloride staining of 293T L cells 48 h after
treatment, showing a substantial increase in nuclear size that is indicative of G2-M arrest.
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cell death, albeit only in the presence of functional MMR, i.e., in
293T L cells. Accumulation of cells with a DNA content of 4n
was observed as early as 30 h, and a sub-G1 peak was evident after
48 h. As expected, nuclei of G2-M arrested 293T L
 cells
appeared considerably larger than in untreated cells (Fig. 1F), but
no apoptotic bodies were detectable at later time points. In addi-
tion, we failed to detect DNA fragmentation (Fig. 1D) and PARP
cleavage (Fig. 1E).
Despite the dramatic impact of the presence of hMLH1 on the
cellular fate in response to MNNG, we detected relatively few genes
differentially transcribed in 293T L cells compared with L 30 h
after treatment (Fig. 3A), as well as at other time points. In addition,
MNNG treatment affected the transcriptome of 293T L cells regard-
less of the MMR status. By multiple regression analysis, we could
distinguish gene regulations induced by the genotoxic treatment per se
from changes after MMR-dependent DNA damage processing. As
shown in Table 2, the genes belonging to the latter category (Table
2A) were not as numerous as those regulated upon MNNG treatment
independently of the MMR status (Table 2B; complete list in Table D,
supplementary material). Most of the significant changes between
MMR-proficient and MMR-deficient cells were recorded at the latest
time point (72 h). Indeed, at this time, we observed in 293T L cells
an augmented expression of genes encoding proteins involved in
signaling such as the kinases SNK, FAK, and CLK1 and the growth
inhibitors PTGER2 (20) and IGFBP7/Mac25 (Ref. 21; Table 2A). The
increased level of IGFBP7/Mac25 mRNA was confirmed by RT-PCR
(Fig. 3B).
The majority of changes induced by MNNG independently of the
MMR status were present already 12 h after treatment. A paradigm is
the transcription factor ATF3 that has been reported to be transcrip-
tionally induced upon DNA damage (22). ATF3 was up-regulated in
293T L cells to the same extent as in TK6 and MT1 (the latter treated
with an equitoxic concentration of MNNG; Fig. 3C). Thus, 293T cells
are likely to sense the MNNG treatment also in the absence of MMR,
as further witnessed by the up-regulation of the two stress response
factors STK39 and GADD34. As p53 is stabilized and inactivated in
Fig. 2. Microarray data and quantitative evaluation of RNA and proteins in TK6 and MT1 cells. The scatter graphs show the overall changes of TK6 (A) and MT1 (B) transcriptomes
upon MNNG treatment (x and y axes: signal values). Each dot represents a gene and the four diagonal lines correspond to different fold changes of expression (i.e., dots outside the
two inner lines represent transcripts the levels of which deviated 2-fold from the central line). Hundreds of dots spreading over the 2-fold change lines (A) indicate dramatic changes
in gene modulation in the TK6 cells upon MNNG treatment. The transcriptome of MT1 cells (B) remained globally unmodified upon similar treatment. N.B., the bottom left parts of
the graphs carry limited significance because transcripts of low abundance are difficult to quantitate reproducibly. C, quantitative analysis of transcripts by RT-PCR. The height of the
bars corresponds to TAC (see “Materials and Methods”) and inversely correlates with the abundance of the transcript (some error bars are very small and not visible in this picture).
GAPDH was used as control. D–H, Western blot analyses (see “Results”). TFIIHp89 and -tubulin: loading controls. I and J, scatter graphs obtained by comparing the basal level of
transcripts in the MMR-proficient cells with the respective MMR-deficient counterparts. A substantial number of genes were differentially expressed in MT1 cells as compared with
TK6 (I). No differences were detectable in 293T L versus L cells (J), except for the two hMLH1probes (arrowed).
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293T cells (Fig. 3D), we did not observe any induction of its tran-
scriptional targets upon treatment. On the contrary, some p53-induc-
ible genes such as p21/WAF1, BAX, and BTG2 were down-regulated.
For p21/WAF1, this type of regulation was associated with a decrease
of the corresponding polypeptide, as confirmed by immunoblot anal-
ysis showed in Fig. 3E. Finally, in contrast to the lymphoblastoid
cells, the cell cycle arrest was not associated with changes in c-myc
RNA and protein levels (Fig. 3E).
Table 1 A selection of the 340 transcripts that significantly changed in TK6 cells upon MNNG treatment
Genes in bold were found up-regulated also in treated WTK1 cells (complete lists in Tables A and C of supplementary material).
Categorya GeneBank access. no. Title Functiona Fold changeb Scorec
Up-regulated genes
Metabolism M29877 L-fucosidase  Glycan metabolism 30.8 7
J03826 Ferrodoxin reductase Electron transport 3.5 7
M30474 GT2 Amino acid metabolism 3.0 7
Cytoskeleton AF001691 Periplakin Cell shape control 20.2 6
X13839 Vascular smooth  actin Cell shape control 4.6 7
AI888563 Smoothelin Cell shape control 2.1 7
U03057 SNL/fascin1 Cell shape control 2.1 7
Signaling AL022310 TNF SF 4/OX40L Cell growth control 16.5 6
U78305 WIP-1 Cell growth control (p53 inducible) 4.8 7
U07358 MAP 3K 12 MAP kinase signaling 2.1 6
Immune response U02388 CYP4F2 Leukotriene metabolism 12.0 6
J00219 INF Growth suppression 8.0 5
Transcription W47047 P8 protein Candidate for metastasis 11.0 5
AA635153 ZNF 79 Transcription factor 5.4 5
U59913 SMAD5 Growth suppression (TGF pathway) 3.6 6
L19871 ATF3 Stress response 3.5 6
U68019 SMAD3 Growth suppression (TGF pathway) 2.4 6
L29277 STAT 3 Growth control (INF pathway) 2.3 7
M97936 STAT1 Pro-apoptotic (INF pathway) 2.2 6
Cell growth AB00584 MIC-1 Growth suppression (p53 inducible) 10.9 7
X16354 CEACAM1 Growth suppression 9.3 6
M14083 PAI-1 Induction of senescence 5.6 6
AF059611 NRP/B (Pig10) Neurogenesis (p53 inducible) 4.8 7
AF038844 DUSP14/MPK6 MAPK inactivation 4.7 7
U72649 BTG 2 Growth suppression (p53 inducible) 4.0 7
AF050110 TIEG Growth suppression (TGF pathway, p53 ind) 3.9 7
U91512 ninjurin1 Neurogenesis 3.8 7
X61123 BTG1 Growth suppression 2.9 7
U66469 CGR19 Growth suppression (p53 inducible) 2.1 6
U51127 IRF5 Growth control (INF pathway) 1.9 7
Cell cycle U33203 mdm2 (isoforms D,E,A) P53 nuclear export (p53 inducible) 5.6 6
U57317 P/CAF Acetylation (p53 activation) 4.7 4
M60974 GADD45 Cell cycle arrest (p53 inducible) 3.9 7
U03106 p21/Waf1 Cell cycle arrest (p53 inducible) 3.9 7
X57348 14-3-3 Cell cycle arrest (p53 inducible) 2.8 7
U83981 GADD34 Cell cycle arrest 2.7 6
U77949 CDC6 Cell cycle control 2.1 7
M92287 Cyclin D3 G1/S cyclin 1.8 7
Apoptosis AF010309 Pig3 Apoptosis induction (p53 inducible) 10.5 7
U82987 PUMA Apoptosis induction (p53 inducible) 2.8 7
U19599 BAX  Apoptosis induction (p53 inducible) 2.2 7
X63717/Z70519 FAS/APO1 Apoptosis induction (death receptor) 2.2 7
L05072 IRF1 Apoptosis induction (INF pathway) 2.1 7
U60519 CASP 10 B Apoptosis induction 2.1 5
L22473 BAX  Apoptosis induction (p53 inducible) 2.1 7
U37518 TNFSF10 Apoptosis induction 2.0 6
U77845 hTRIP Apoptosis induction 2.0 6
U16811 Bak Apoptosis induction (p53 inducible) 1.9 6
DNA repair D21089 XP-C Nucleotide excision repair (p53 inducible) 4.3 7
U18300 XP-E/DDB2 Nucleotide excision repair (p53 inducible) 4.3 7
AF034956 RAD 51 L3 Recombination 2.1 5
M36067 Ligase I DNA ligation 2.0 7
X95152 BRCA2 exon2 Recombination 2.0 6
Down-regulated genes
Cell growth V00568 c-myc Growth stimulation 3.1 7
U52682 IRF 4 Growth stimulation 2.7 7
U96876 Insulin induced gene 1 Growth stimulation 1.9 7
X02160 Insulin receptor Growth stimulation 1.9 5
Cell cycle AF023612 DIM1 Essential for mitosis 2.4 4
M25753 Cyclin B1 related G2/M transition 1.9 7
U11791 Cyclin H CDC2 activation 1.8 7
Protein folding AI912041 HSP E1 Heat shock protein 2.3 7
M59830 HSP70-2 Heat shock protein 2.3 6
Y00371 HSC 70 Heat shock protein 2.1 7
M11717 HSP 70 Heat shock protein 2.0 7
Metabolism S68805 AGAT Energetic metabolism 2.4 6
X66435 HMGCS1 Lipid metabolism 2.2 6
D78130 Squalene Epoxidase Lipid metabolism 2.1 7
X60221 ATP5F1 Energetic metabolism 2.0 5
Translation M15353 EIF 4E Protein synthesis 2.1 6
a Derived from LocusLink and SwissProt databases or recent publications in case of incomplete annotations.
b Average signal of MNNG-treated TK6 cells versus average signal of untreated TK6 cells.
c See “Materials and Methods.”
8162
TRANSCRIPTIONAL RESPONSE TO DNA METHYLATION DAMAGE
DISCUSSION
In this work, we investigated the MMR-dependent changes in gene
expression occurring upon treatment with the DNA-methylating agent
MNNG, using two different human cellular models. Our aim was to
mimic what happens in normal and tumor cells exposed to agents that
methylate the O6-position of deoxyguanosine because it is the proc-
essing of this lesion by the MMR system that governs the cytotoxicity
of these drugs (see “Introduction”). This is the first study in which the
global gene expression in human cells treated with methylating agents
has been investigated. Similar studies were performed in yeast but
using methyl methanesulfonate, which does not methylate on O6-
deoxyguanosine (23, 24). In addition, there is no evidence that
the toxicity of methylating agents in yeast is affected by the MMR
status (6).
MNNG efficiently killed the MMR-proficient lymphoblastoid TK6
cells in which a cell cycle delay in S phase was followed by apoptosis.
This phenomenon could be ascribed to the attempts of the MMR
system to process O6-meG/T mismatches during DNA replication (see
“Introduction”). The same repair process is probably responsible for
the dramatic transcriptional response leading to cell death. In contrast,
MNNG failed to cause even mild perturbation of the cell cycle in the
hMSH6-deficient MT1 cells. Microarray experiments showed that the
transcriptome of MT1 cells was globally unmodified, whereas in TK6
cells, the treatment had a large impact on gene expression. The
presence of many p53-inducible genes and TGF- effectors among
the most up-regulated transcripts in TK6 cells indicates that these two
pathways are both activated to arrest cell proliferation. Our data are
consistent with a previous microarray experiment in which p53-
regulated genes were identified using a human lung cancer cell line
expressing temperature-sensitive p53 (25). We detected up-regulation
of five DNA repair genes upon MNNG treatment, at least two, XP-C
and DDB2, known to carry p53-responsive elements in their promot-
ers (26, 27). Our microarray data revealed that the activation of
apoptosis was only partially accomplished through p53-inducible ef-
fectors (PIG3, BAX, and PUMA; Refs. 28–31). The up-regulation of
IFN- and its downstream effectors signal transducers and activators
of transcription 1 and IRF1, as well as the induction of Fas/APO1 and
some members of the tumor necrosis factor superfamily, suggest also
an activation of a proapoptotic cross-talk among cells through the
death receptor system (32–34). Surprisingly, the negative modulator
of cell cycle p21/WAF1, although transcriptionally activated at 30 h,
was not up-regulated at the protein level at this time, when cells were
delayed in S phase. That p21/WAF1 is dispensable for cell cycle arrest
in this cell cycle phase has already been suggested by the observation
that a transient intra-S-phase checkpoint can be p21/WAF1 independ-
ent (35). Thus, the fact that the protein level of p21/WAF1 was not
changed 30 h after treatment despite an increase in its RNA suggests
that a posttranscriptional mechanism may control this function at this
time point to promote DNA repair (36) and eventually allow apoptosis
(37, 38).
Interesting findings regarding the role of p53 in lymphoblastoid
cells treated with low doses of MNNG were gathered when we
examined the p53-mutated WTK1 cell line. Microarray analysis (Ta-
ble 1, genes in bold and Table C, supplementary material) revealed
up-regulation of death receptors (Fas/APO1 and TNFRSF 9 and 17)
and activation of the TGF--dependent signaling through up-regula-
tion of SMAD5 and TIEG (18). Surprisingly, the transcripts of some
cell cycle inhibitors such as p21/WAF1, GADD45, CGR19, and
BTG2, generally thought to be p53-dependent, were up-regulated to
the same extent as in TK6, pointing to a transcriptional activation
Fig. 3. Microarray data and quantitative evaluation of transcripts and proteins in 293T L/L cells. A, several genes were differentially expressed in L cells compared with
L 30 h after MNNG treatment (see Table 2 for details). The arrows show the two probes for hMLH1. B, quantitative RT-PCR analysis of insulin-like growth factor binding protein
7, the 2.6-fold up-regulation of which in L compared with L was confirmed by the difference in TAC (1.5 cycles earlier in L). GAPDH was used as control. C, quantitative
RT-PCR analysis of ATF3. Significant increase of this transcript was recorded in all of the cell lines treated with equitoxic amounts of MNNG. D and E, Western blot analyses showing
p53 stabilization (D), unchanged c-myc levels and down-regulation of p21 protein levels (E). TFIIHp89 and -tubulin: loading controls. Dox: addition of doxycycline turns off hMLH1
expression.
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Table 2 Genes
A. Genes whose expression significantly varied upon MNNG treatment in 293T L cells compared with L at the time point indicated
GeneBank access no. Title Categorya Functiona Time point(s)b
L  L L19182 IGFBP7 Signal transduction Growth suppression 72
AF059617 SNK Signal transduction Mitogenic response 72
HG3075-HT3236 FAK Signal transduction Integrin signaling 72
HG3484-HT3678 CLK1 Signal transduction Dual specificity kinase 72
L06797 CXCR4 Signal transduction Chemokine receptor (Immune response) 72
HG2167-HT2237 PK HT31 Signal transduction Scaffolding for PKA 72
U19487 PTGER2 Signal transduction Prostaglandin E2 receptor EP2 72
U97669 Notch homolog 3 Signal transduction Cell differentiation 72
AB022718 DEPP ? Decidual protein induced by progesterone 72
U59632 PNUTL1 Cytoskeleton Cell shape 72
AB002323 DNCH1 Cytoskeleton Spindle formation 72
U66689 ABCC6 Membrane fraction Small molecule transport 72
X54871 RAB5B Membrane fraction Vesicle transport 72
M86917 OSBP Lipid metabolism Oxysterol binding protein 12
L  L Y00067 NEF 3 Cytoskeleton Intermediate filament 72
W28588 NEFL Cytoskeleton Neurofilament 12
AB007892 CDC5-like Cell cycle Spliceosome, G2/M transition 72
M27396 ASNS Metabolism Asparagine synthetase 72
AB002345 PER2 Metabolism Not known 30
U31875 DHRS2 Energetic metabolism Alcohol dehydrogenase 30, 72
X03473 H1F0 Nucleosome Histone 72
AL049223 SCAMP1 Membrane trafficking Endocytosis 72
AB011141 SMADIP1 Transcription SMAD interacting protein 12
U79273 clone23933 ? Homology to Alu sequence and EIF4A 72
B. A selection of genes that were up- or down-regulated in 293T L cells upon MNNG treatment independently of the hMLH1 expression (for a complete list, see Table D of
supplementary material)
GeneBank Title Categorya Functiona Time point(s)c
Up-regulated V01512 c-fos Signal transduction Growth and apoptosis control 12,30,72
J04111 c-jun Signal transduction Growth and apoptosis control 72
U27193 DUSP8 Signal transduction JNK-p38 inactivation 12,30,72
X68277 DUSP1 Signal transduction JNK inactivation 12,30,72
AJ131693 AKAP9 Signal transduction Scaffolding for PKA 72
J03358 FER Signal transduction Kinase 72
AA224832 STK39 (SPAK) Signal transduction Stress response 12
U83981 GADD34 Cell cycle Cell growth and apoptosis 30, 72
L19871 ATF3 Transcription Stress response 12,30,72
U66619 SMARCD3 Transcription Chromatin modeling 12,30,72
AB007931 Rb-assoc factor 600 Transcription Zinc finger protein 12,30,72
S78296 INA Cytoskeleton Intermediate filament 12,30,72
M13452 lamin A Cytoskeleton Cell shape 12,30,72
AA669799 ASMTL Metabolism Acetylserotonin methyltransferase-like 12,30,72
D13642 SF3b RNA binding prot Splicing factor 12,30,72
D64108 DMC1 DNA repair Recombination 30, 72
Down-regulated U59305 PK428 Signal transduction Ser/Thr kinase 12,30,72
U50062 RIPK1 Signal transduction Ser/Thr kinase 12,30,72
M34181 PKA catalytic sub ▫ Signal transduction Kinase activity 12, 30
D88532 PI3K reg sub 3PIK 3R3 Signal transduction Insulin pathway 12,30,72
AF007567 IRS4 Signal transduction Insulin pathway 12,30,72
L27560 IGFBP5 Signal transduction Growth stimulation 12
Z71929 FGFRec 2 Signal transduction Growth stimulation 12,30,72
X76061 Rb-like 2 (p130) Signal transduction Growth control 12, 30
Z11695 MAPK1 Signal transduction Stress response 12,30,72
L33881 PKC iota Signal transduction Kinase 12, 30
U24153 PAK2 Signal transduction Apoptotic signaling 12,30,72
U03106 p21 Cell cycle Growth suppression 12,30,72
AF023158 CDC14B Cell cycle M-phase regulator 12,30,72
L07648 MXI1 Cell cycle c-myc inhibitor 12, 30
U72649 BTG2 Cell growth Growth suppression 12, 30
L22475 BAX  Apoptotic signaling Apoptosis 12,30,72
U19599 BAX  Apoptotic signaling Apoptosis 12,30,72
U65092 MSG1 Transcription Cbp/p300-interacting factor 30, 72
AF040963 SMAD4 Transcription Growth suppression 12,30,72
M27691 CREB1 Transcription G-protein signaling 12,30,72
M88163 SMARCA1 Transcription Chromatin modeling 12
X13839 Vascular smooth  actin Cytoskeleton Cell shape 12,30,72
X07834 SOD2 Metabolism Oxidative stress response 12,30,72
AA877795 ATP6V1D Metabolism ATP synthesis 12,30,72
NM001098 Aconitase Metabolism Energy metabolism 12, 30
M10905 Fibronectin 1 Extracellular matrix Cell adhesion 12, 30
L13210 Mac-2 bind protein Extracellular matrix Scavenger receptor 12,30
M61916 Laminin  1 Extracellular matrix Basement membrane protein 12, 30
M82809 Annexin IV Membrane fraction Phospholipase A2 inhibitor 12, 30
U50410 Glypican3 Membrane fraction Growth control ? 12, 30
X59841 PBX3 Development Transcription factor 12,30,72
a Derived from LocusLink and SwissProt databases or recent publications in case of incomplete annotations.
b Time point at which the multiple regression analysis showed a statistically significant (P  0.05) interaction between the presence of hMLH1 and the time after treatment.
c Time point at which the multiple regression analysis showed a significant (P  0.05) up- or down-regulation of the gene upon MNNG treatment regardless of the presence of
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independent of p53. In contrast, the proapoptotic p53-targets BAX,
PUMA, and PIG3 were unchanged. These findings suggest that
MMR-proficient lymphoblastoid cells can use alternative pathways to
trigger cell death independently of the transcriptional activity of p53.
The absence of any transcriptional response in MT1 cells exposed
to equimolar (0.4 M) doses of MNNG could be ascribed to mecha-
nisms other than MMR deficiency. We could exclude resistance
mediated by detoxifying enzymes because MGMT and GSH-S-trans-
ferases have the same pattern of expression as in TK6. In addition, the
integrity of the p53-dependent pathway in MT1 was ascertained upon
exposure to equitoxic doses (23 M) of MNNG. However, from the
basal gene expression pattern (Table B, supplementary material), it
would appear that MT1 cells have acquired a more transformed
phenotype than TK6. Seven tumor antigens (GAGE isoforms and
BAGE) were among the most up-regulated transcripts in MT1 com-
pared with TK6, as well as the tumorigenic factor PRKAC (catalytic
subunit of PKA). Different isoforms of the tumor marker CD44, found
associated with inhibition of apoptosis and growth advantage (39),
were overexpressed, whereas the transcript for the structural protein
SNL/fascin1, reported to play an important role in cell adhesion and
migration of peripheral blood cells (40), was 40 times less abundant.
Finally, the balance between proapoptotic and antiapoptotic factors
was strongly biased in favor of the latter (see “Results”). Because
these findings demonstrated that TK6 and MT1 cells cannot be
considered isogenic as previously invoked, we extended our study to
the truly isogenic model 293T L/L.
As shown for the lymphoblastoid cell lines, only 293T cells with a
functional MMR system were sensitive to MNNG, although the
features of the cellular response of 293T L differed from TK6 in
that a G2-M checkpoint was activated after a transient S-phase slow-
down and cell death was delayed. The absence of any sign of apo-
ptosis (upon MNNG and Fas ligand treatments) might be explained by
the general tolerance of this cell line to apoptotic stimuli. This
phenotype results, at least in part, from the expression of adenovirus
E1A and E1B proteins and of SV40 large T antigen (12) that brings
about inactivation of p53- (41, 42) and of TGF--dependent pathways
(43). Indeed, none of the effectors of p53 and TGF- pathways were
transcriptionally induced upon MNNG treatment and some such as the
growth inhibitors p21/WAF1, BTG2, and SMAD4, as well as the
proapoptotic BAX, were down-regulated. Interestingly, this type of
regulation was detected also in the absence of MMR, presumably as
a global response of the 293T L aimed at surviving the treatment.
This is also supported by the enhanced transcription in both 293T L
and L of the oncogenes c-fos and c-jun. Among the cellular
processes regulated by c-Fos and c-Jun, a stimulation of cell cycle
progression via repression of p21/WAF1 transcription has been re-
ported (44). A synergistic effect might be accomplished by the up-
regulation of the mitogen-activated protein kinase phosphatases
DUSP1 and DUSP 8 (Table 2), which have been shown to be involved
in the dephosphorylation and inactivation of the stress-inducible and
antiproliferative mitogen-activated protein kinases c-Jun NH2-termi-
nal kinase and p38 (45, 46). This type of gene regulation may suggest
that 293T L cells sensed the treatment also in the absence of
functional MMR. This is additionally witnessed by the up-regulation,
independently of the MMR-status, of the transcription factor ATF3,
previously correlated with the response to genotoxic agents in a
p53-dependent and -independent fashion (22).
These findings suggest that MNNG induces a general response in
293T L characterized by an increase of survival signals. Notwith-
standing this, 293T L cells, where the O6-meG/T mismatches can
be addressed by the MMR, stopped cycling, and eventually died.
Indeed, in these cells we detected posttranslational modifications that
accompanied the G2-M arrest (i.e., CHK1 and CHK2 phosphoryla-
tion, CDC25A degradation, and CDC2 Tyr15 phosphorylation4), but
in contrast to lymphoblastoid cells, activation of the G2-M checkpoint
was reflected in only a moderate transcriptional response. This might
be ascribed to the inactivation of pRb by the transfected E1A that
brings about deregulation of E2F activity, a pivotal transcription
factor acting in response to cell cycle modulators (47). Microarray
data failed to help us identify the pathways responsible of cell death
in these cells, yet some signaling molecules, differentially transcribed
in MMR-proficient 293T L cells upon treatment, might be biologi-
cally relevant in determining their cellular fate. One example is the
up-regulation of the tumor suppressor insulin-like growth factor bind-
ing protein 7/Mac25 that was reported to be down-regulated in some
breast cancer cells (21) and increased in cells committed to death by
senescence or apoptosis (48, 49). Taken together, these data showed
that although MNNG can induce a general stress response in 293T L
cells, its cytotoxicity depends exclusively on the recognition and
processing of DNA damage by the MMR system. The absence of
MGMT in these cells, as well as in TK6 cells, enabled us to use doses
of MNNG that were so low as to prevent any MMR-independent
cytotoxicity.
In conclusion, we demonstrated that in the presence of DNA
methylation damage, the MMR system swings the balance between
survival and death in favor of the latter. The type of response strongly
depends on the cellular background and relies on the signaling path-
ways available to the cells. Although p53 may be one of the main
effectors of cell death induced by MNNG, its inactivation does not
prevent cell death. The experiments with 293T cells showed that even
in the presence of strong survival signals, a situation that might mimic
tumor environment, MMR is sufficient to activate pathways leading to
proliferation arrest and eventually cell death. Thus, MMR most likely
plays a crucial role in the efficacy of methylating agents in cancer
therapy. Unfortunately, by playing a similar role also in rapidly
proliferating normal tissues such as bone marrow and gastrointestinal
mucosa, MMR is responsible for the toxicity of this treatment. To
prevent side effects, lower doses of methylating agents would have to
be deployed, which requires that the level of MGMT in the tumor be
reduced. Targeted down-regulation of this enzyme in MMR- and
MGMT-positive tumors is subject to investigation.
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